Health AI Central
Peer-Reviewed Publication
Clin Ther2026July 8, 2026Journal Article

Effectiveness and Safety of Cannabis-Based Products for Refractory Epilepsy From Real-World Evidence.

Mariana Dias Lula1, Ronaldo Portela2, Daniel Marques Mota3, Juliana Álvares-Teodoro4, Maria Laura Silva5, Augusto Afonso Guerra-Júnior6, Cristina Mariano Ruas7
1Postgraduate Program in Medicines and Pharmaceutical Care, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; SUS Collaborating Center for Health Technology Assessment and Excellence, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Brazilian Health Regulatory Agency (Anvisa), Distrito Federal, Brazil. Electronic address: maridlula@gmail.com.
2Federal District Department of Health, Distrito Federal, Brazil.
3Brazilian Health Regulatory Agency (Anvisa), Distrito Federal, Brazil.
4SUS Collaborating Center for Health Technology Assessment and Excellence, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Department of Social Pharmacy, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
5School of Pharmacy, Université de Bordeaux, Bordeaux, France.
6SUS Collaborating Center for Health Technology Assessment and Excellence, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Department of Social Pharmacy, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, United Arab Emirates.
7Department of Social Pharmacy, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
PubMed DOI

Abstract

PURPOSE: Cannabis-based products have emerged as a potential therapeutic option for refractory epilepsy; however, real-world evidence remains limited, particularly within public health systems. This study evaluated the effectiveness and safety of cannabis-based products among patients with refractory epilepsy treated through Brazil's public health system and explored factors associated with percei…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.